Welcome to LookChem.com Sign In|Join Free
  • or
Isopropyl 2-[6-(N-[4-(1H-pyrazol-1-yl)benzyl]pyridine-3-sulfonamidomethyl)pyridin-2-yl]aminoacetate, also known as Omidenepag Isopropyl, is a derivative of Omidenepag (O635205). It is a novel selective, non-prostanoid EP2 receptor agonist. isopropyl 2-[6-(N-[4-(1H-pyrazol-1-yl)benzyl]pyridine-3-sulfonamidomethyl)pyridin-2-yl]aminoacetate is characterized by its unique chemical structure, which includes a pyridine-based core with various substituents that contribute to its biological activity.
Used in Pharmaceutical Industry:
Isopropyl 2-[6-(N-[4-(1H-pyrazol-1-yl)benzyl]pyridine-3-sulfonamidomethyl)pyridin-2-yl]aminoacetate is used as a therapeutic agent for the treatment of Glaucoma. It functions as a selective EP2 receptor agonist, which helps to lower intraocular pressure, a key factor in managing glaucoma. isopropyl 2-[6-(N-[4-(1H-pyrazol-1-yl)benzyl]pyridine-3-sulfonamidomethyl)pyridin-2-yl]aminoacetate's selectivity for the EP2 receptor allows for targeted treatment with potentially fewer side effects compared to other glaucoma medications.
Used in Ophthalmology:
In the field of ophthalmology, isopropyl 2-[6-(N-[4-(1H-pyrazol-1-yl)benzyl]pyridine-3-sulfonamidomethyl)pyridin-2-yl]aminoacetate is used as a novel treatment option for patients suffering from glaucoma. Its role as a selective EP2 receptor agonist makes it a promising candidate for developing new therapies that can effectively reduce intraocular pressure and slow the progression of this vision-threatening disease.

1187451-19-9

Post Buying Request

1187451-19-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1187451-19-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1187451-19-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,7,4,5 and 1 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1187451-19:
(9*1)+(8*1)+(7*8)+(6*7)+(5*4)+(4*5)+(3*1)+(2*1)+(1*9)=169
169 % 10 = 9
So 1187451-19-9 is a valid CAS Registry Number.

1187451-19-9Downstream Products

1187451-19-9Relevant academic research and scientific papers

Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl

Iwamura, Ryo,Tanaka, Masayuki,Okanari, Eiji,Kirihara, Tomoko,Odani-Kawabata, Noriko,Shams, Naveed,Yoneda, Kenji

, p. 6869 - 6891 (2018/07/21)

EP2 receptor agonists are expected to be effective ocular hypotensive agents; however, it has been suggested that agonism to other EP receptor subtypes may lead to undesirable effects. Through medicinal chemistry efforts, we identified a scaffold bearing a (pyridin-2-ylamino)acetic acid moiety as a promising EP2-selective receptor agonist. (6-((4-(Pyrazol-1-yl)benzyl)(pyridin-3-ylsulfonyl)aminomethyl)pyridin-2-ylamino)acetic acid 13ax (omidenepag, OMD) exerted potent and selective activity toward the human EP2 receptor (h-EP2). Low doses of omidenepag isopropyl (OMDI), a prodrug of 13ax, lowered intraocular pressure (IOP) in ocular normotensive monkeys. OMDI was selected as a clinical candidate for the treatment of glaucoma.

N-SUBSTITUTED SULFONAMIDE COMPOUND AND METHOD FOR PRODUCING SAME

-

, (2017/07/06)

The present invention relates to a method for producing N-substituted sulfonamide compounds including a step of reacting a sulfonamide compound of general formula (1) with a halogenated organic compound of general formula (2) in the presence of cesium carbonate or potassium carbonate in an organic solvent to produce an N-substituted sulfonamide compound of general formula (3).

PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA

-

Page/Page column 100, (2012/02/15)

The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1): wherein R1, R2 and R3 each independe

PYRIDYLAMINOACETIC ACID COMPOUND

-

Page/Page column 98, (2011/01/11)

The present invention provides a novel pyridylaminoacetic acid compound represented by the following formula (1): (wherein R1, R2, R3, Y and Z are as defined in the description and claims), or a pharmacologically acceptabl

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1187451-19-9